Sionna Therapeutics, Inc. (SION) stock
SIONNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.07−0.05 (-1.60%)
Close on Nov 17, 2026Market cap $138.80MP/E –Yield –
Sionna Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Sionna Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $78.02M, up 31.5% year over year. For fiscal 2025 it was $60.26M, up 5.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.26M | +5.2% |
| FY2024 | Dec 31, 2024 | $57.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $22.03M | +37.3% |
| Q2 FY2026 | Jun 30, 2026 | $21.86M | +42.1% |
| Q1 FY2026 | Mar 31, 2026 | $18.96M | +38.7% |
| Q4 FY2025 | Dec 31, 2025 | $15.17M | +6.4% |
| Q3 FY2025 | Sep 30, 2025 | $16.04M | -34.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.38M | +86.8% |
| Q1 FY2025 | Mar 31, 2025 | $13.67M | +33.7% |
| Q4 FY2024 | Dec 31, 2024 | $14.25M | – |
| Q3 FY2024 | Sep 30, 2024 | $24.58M | – |
| Q2 FY2024 | Jun 30, 2024 | $8.23M | – |
| Q1 FY2024 | Mar 31, 2024 | $10.22M | – |
See a number that looks wrong?